• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by CryoPort Inc.

    6/14/24 4:31:02 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYRX alert in real time by email
    S-8 1 tm2417091d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on June 14, 2024

    Registration No. 333- 

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    Cryoport, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Nevada

    (State or other jurisdiction of
    incorporation or organization)

    88-0313393

    (I.R.S. Employer
    Identification No.)

    112 Westwood Place, Suite 350

    Brentwood, TN 37027
    (Address of principal executive offices, including zip code)

     

     

     

    Cryoport, Inc. 2018 Omnibus Equity Incentive Plan

    (Full title of the plan)

     

     

     

    Robert Stefanovich
    Cryoport, Inc.

    Chief Financial Officer

    112 Westwood Place, Suite 350

    Brentwood, TN 37027

    (949) 470-2300

    (Name, address and telephone number, including area code, of agent for service)

     

     

     

    With a copy to:

    Kevin Zen

    Snell & Wilmer L.L.P.

    600 Anton Boulevard., Suite 1400

    Costa Mesa, CA 92626

    (714) 427-7000

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer ¨ Accelerated filer x
    Non-accelerated filer ¨  Smaller reporting company  ¨
      Emerging growth company  ¨


     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This registration statement is being filed solely for the registration of 2,500,000 additional shares of common stock, $0.001 par value per share, of Cryoport, Inc., a Nevada corporation (the “Company”), for issuance pursuant to the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (as amended, the “Plan”). Accordingly, pursuant to General Instruction E to Form S-8, the contents of the Company’s prior registration statements relating to the Plan (Nos. 333-225387 and 333-257368) are hereby incorporated by reference in this registration statement, except as revised in Part II of this registration statement.

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Company with the Securities and Exchange Commission (the “Commission”) are incorporated by reference into this registration statement and are deemed to be a part hereof from the date of filing:

     

    1.The Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on March 13, 2024 (the “Form 10-K”).

     

    2.The Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, filed with the Commission on May 8, 2024.

     

    3.The Company’s Current Reports on Form 8-K, filed with the Commission on February 15, 2024 and May 22, 2024.

     

    4.The description of the Company’s common stock contained in its Registration Statement on Form 8-A (No. 001-34632), filed with the Commission on July 22, 2015, and any amendment or report filed for the purpose of updating such description, including Exhibit 4.1 to the Form 10-K.

     

    All documents filed by the Company pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (other than Current Reports on Form 8-K furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items), subsequent to the filing of this registration statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this registration statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

     

    Item 8. Exhibits.

     

    Exhibit
    Number

     

    Description

     

    Page or Method of Filing

     
    4.1 Amended and Restated Articles of Incorporation of Cryoport, Inc. Incorporated by reference to Exhibit 3.1 of the Company’s Form 10-Q filed with the Commission on November 9, 2012
    4.2 Amended and Restated Bylaws of Cryoport, Inc. Incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed with the Commission on February 8, 2016
    4.3 Amended and Restated Certificate of Designation of Class A Preferred Stock Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on March 30, 2015
    4.4 Certificate of Designation of Class B Preferred Stock Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on February 20, 2015
    4.5 Amendment to Certificate of Designation of Class B Preferred Stock Incorporated by reference to Exhibit 3.6 to the Company’s Amendment No. 1 to Registration Statement on Form S-1 filed with the Commission on April 17, 2015
    4.6 Certificate of Change filed with the Nevada Secretary of State on May 12, 2015 Incorporated by reference to Exhibit 3.7 to the Company’s Annual Report on Form 10-K filed with the Commission on May 19, 2015
    4.7 Amendment to Certificate of Designation of Class A Preferred Stock Incorporated by reference to Exhibit 3.8 to the Company’s Amendment No. 4 to Registration Statement on Form S-1 filed with the Commission on June 22, 2015
    4.8 Amendment to Certificate of Designation of Class B Preferred Stock Incorporated by reference to Exhibit 3.9 to the Company’s Amendment No. 4 to Registration Statement on Form S-1 filed with the Commission on June 22, 2015
    4.9 Amendment to Certificate of Designation of Class A Preferred Stock Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on September 4, 2015
    4.10 Amendment to Certificate of Designation of Class B Preferred Stock Incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the Commission on September 4, 2015
    4.11 Certificate of Amendment filed with the Nevada Secretary of State on November 23, 2015 Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on December 1, 2015
    4.12 Certificate of Amendment filed with the Nevada Secretary of State on May 30, 2018 Incorporated by reference to Exhibit 3.12 of the Company’s Annual Report on Form 10-K filed with the Commission on March 13, 2019
    4.13 Certificate of Designation of 4.0% Series C Convertible Preferred Stock of Cryoport, Inc. Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Commission on October 1, 2020
    5.1 Opinion of Snell & Wilmer L.L.P. Filed herewith
    23.1 Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm Filed herewith
    23.2 Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm Filed herewith
    23.3 Consent of Snell & Wilmer L.L.P. Included as part of Exhibit 5.1
    24.1 Power of Attorney Included on the signature page hereto
    99.1 Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (as amended by the First Amendment, the Second Amendment and the Third Amendment, effective May 17, 2024)

    Incorporated by reference to Appendix A of the Company’s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 3, 2024

     

    107 Filing Fee Table Filed herewith

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Brentwood, State of Tennessee, on June 14, 2024.

     

      CRYOPORT, INC.
         
      By: /s/ Robert S. Stefanovich
      Name: Robert S. Stefanovich
      Title: Chief Financial Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below hereby constitutes and appoints Jerrell W. Shelton and Robert S. Stefanovich, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with any and all exhibits thereto, and other documents in connection therewith, with the Commission, and hereby grants to such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature Title Date
         

    /s/ Jerrell W. Shelton

    Jerrell W. Shelton

     President, Chief Executive Officer and Director
    (Principal Executive Officer)
    June 14, 2024
         

    /s/ Robert S. Stefanovich

    Robert S. Stefanovich

    Chief Financial Officer
    (Principal Financial and Accounting Officer)
    June 14, 2024
         

    /s/ Richard Berman

    Richard Berman

    Director June 14, 2024
         

    /s/ Daniel M. Hancock

    Daniel M. Hancock

    Director June 14, 2024
         

    /s/ Robert Hariri, M.D., Ph.D.

    Robert Hariri, M.D., Ph.D.

    Director June 14, 2024
         

    /s/ Ramkumar Mandalam, Ph.D.

    Ramkumar Mandalam, Ph.D.

    Director June 14, 2024
         

    /s/ Ram Jagannath

    Ram Jagannath

    Director June 14, 2024
         

    /s/ Linda Baddour

    Linda Baddour

    Director June 14, 2024

     

     

     

     

    Get the next $CYRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYRX

    DatePrice TargetRatingAnalyst
    8/6/2025Sector Weight → Overweight
    KeyBanc Capital Markets
    8/6/2025$16.00Market Perform → Outperform
    Leerink Partners
    7/22/2025$13.00Overweight
    Stephens
    3/24/2025$10.00Neutral → Buy
    UBS
    12/19/2024$11.00Buy
    Guggenheim
    12/19/2024$11.00Buy
    Canaccord Genuity
    8/7/2024$20.00 → $8.00Buy → Hold
    Jefferies
    7/31/2024$19.00 → $15.00Neutral → Buy
    B. Riley Securities
    More analyst ratings

    $CYRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cryoport Systems Wins 2025 BioTech Breakthrough Award For "BioServices Innovation of the Year"

    LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe, today announced that Cryoport Systems, a subsidiary of Cryoport, Inc. (NASDAQ:CYRX), a leader in temperature-controlled supply chain solutions for the Life Sciences with a focus on regenerative medicine, today announced the Safepak® Soft System 1800 has been selected as "BioServices Innovation of the Year" in the fifth annual BioTech Breakthrough Awards program. The Safepak Soft System 1800 is a secondary packaging solution that combines proprieta

    11/6/25 12:30:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport Reports Third Quarter 2025 Financial Results

    Third quarter revenue increased 15% year-over-year to $44.2 millionCommercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 millionLife Sciences Services revenue grew 16% year-over-year, including a 21% rise in BioStorage/BioServices revenue Life Sciences Products revenue grew 15% year-over-yearCompany updates full year 2025 revenue guidance of $170 to $174 millionNASHVILLE, Tenn., Nov. 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2025. Provided in

    11/4/25 4:05:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport Continues to Set New Benchmarks for the Global Regenerative Medicine Supply Chain

    First Global Supply Chain Solutions Company to Achieve ISO 21973 Certification, Ensuring Highest Transport Safety, Traceability, and Integrity Standards for Cell and Gene Therapies NASHVILLE, Tenn., Oct. 30, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or "the Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that Cryoport Systems, a Cryoport company, has successfully achieved certification under ISO 21973:2020, the international standard for transportation of human cells for therapeutic use published by the International Organization for Standardization (ISO). This milestone underscores Cryoport Systems' comm

    10/30/25 8:30:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cryoport upgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets upgraded Cryoport from Sector Weight to Overweight

    8/6/25 7:50:22 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Cryoport from Market Perform to Outperform and set a new price target of $16.00

    8/6/25 7:21:40 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens resumed coverage on Cryoport with a new price target

    Stephens resumed coverage of Cryoport with a rating of Overweight and set a new price target of $13.00

    7/22/25 7:52:13 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mandalam Ramkumar sold $115,540 worth of shares (11,570 units at $9.99), decreasing direct ownership by 13% to 80,758 units (SEC Form 4)

    4 - Cryoport, Inc. (0001124524) (Issuer)

    12/12/25 5:30:13 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hariri Robert J exercised 50,000 shares at a strike of $2.66 and sold $242,738 worth of shares (25,000 units at $9.71), increasing direct ownership by 95% to 51,275 units (SEC Form 4)

    4 - Cryoport, Inc. (0001124524) (Issuer)

    9/12/25 5:30:14 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hariri Robert J sold $43,000 worth of shares (5,000 units at $8.60), decreasing direct ownership by 16% to 26,275 units (SEC Form 4)

    4 - Cryoport, Inc. (0001124524) (Issuer)

    8/29/25 6:46:12 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.

    SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)

    2/5/26 4:56:32 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.

    SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)

    11/12/25 2:15:35 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by CryoPort Inc.

    10-Q - Cryoport, Inc. (0001124524) (Filer)

    11/6/25 2:33:28 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Leadership Updates

    Live Leadership Updates

    View All

    Moffitt Cancer Center and Cryoport Announce Strategic Collaboration

    Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 /PRNewswire/ -- Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL, a 775-acre global innovation life sciences campus, and Cryoport, Inc. (NASDAQ:CYRX), a global leader in supply chain solutions for the life sciences industry, today announced a strategic collaboration that will provide CRYOGENE's state-of-the-art biorepository services to Speros in Pasco County, Florida. Cryoport's CRYOGENE business unit is a leading biorepository for the life sciences industry that i

    1/14/25 8:30:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport Announces Appointment of Linda Baddour to its Board of Directors

    NASHVILLE, Tenn., March 3, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has elected Linda Baddour as a member of the Board, effective March 15, 2021. Linda Baddour is a senior executive with over twenty years of experience in healthcare, life sciences and pharmaceuticals. "Our corporate governance underpins all that we do at Cryoport and we are delighted to strengthen our Board as we leverage our newly expanded global footprint and advanced temperature-controlled supply chain platform to spur our growth," said Jerrell She

    3/3/21 4:08:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Appoints Martin Schmieg to Board of Directors

    BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously served as a member of BriaCell’s Board of Directors from 2016 to 2019, Mr. Schmieg is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries with 40 years of business experience. He currently serves as Co-Founder and CEO of ClearIt, L

    12/1/20 6:30:00 AM ET
    $BCTX
    $CLBS
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Managed Health Care

    $CYRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CryoPort Inc.

    SC 13G - Cryoport, Inc. (0001124524) (Subject)

    11/14/24 4:02:52 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

    SC 13G/A - Cryoport, Inc. (0001124524) (Subject)

    11/14/24 1:34:13 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

    SC 13G/A - Cryoport, Inc. (0001124524) (Subject)

    11/13/24 7:16:51 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Financials

    Live finance-specific insights

    View All

    Cryoport Reports Third Quarter 2025 Financial Results

    Third quarter revenue increased 15% year-over-year to $44.2 millionCommercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 millionLife Sciences Services revenue grew 16% year-over-year, including a 21% rise in BioStorage/BioServices revenue Life Sciences Products revenue grew 15% year-over-yearCompany updates full year 2025 revenue guidance of $170 to $174 millionNASHVILLE, Tenn., Nov. 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2025. Provided in

    11/4/25 4:05:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport to Report Third Quarter 2025 Financial Results on November 4, 2025

    NASHVILLE, Tenn., Oct. 21, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the third quarter ended September 30, 2025 on Tuesday, November 4, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Third Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p

    10/21/25 8:00:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport Reports Second Quarter 2025 Financial Results

    Second quarter revenue increased 14% year-over-year to $45.5 millionCommercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 millionLife Sciences Services revenue rose 21% year-over-year, including a 28% increase in BioStorage/BioServices revenue Launched strategic partnership agreement with the DHL Group; closed CRYOPDP divestitureCompany reaffirms full year 2025 revenue guidance of $165 to $172 millionNASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and fir

    8/5/25 4:19:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care